Introduction to Anchiano Therapeutics Ltd.
Anchiano Therapeutics Ltd. stands as a beacon of innovation in the oncology biotechnology sector, dedicated to discovering and developing next-generation therapies for cancer patients. Headquartered in Jerusalem, Israel, with a strong operational presence in the United States, the company has carved a niche for itself by focusing on tumor microenvironment modulation and immune-oncology. Founded on rigorous scientific research and a commitment to addressing unmet medical needs, Anchiano Therapeutics Ltd. has rapidly evolved into a respected name among healthcare professionals, investors, and regulatory bodies. The company’s robust pipeline, which includes small molecules and biologics targeting key pathways in cancer progression, reflects its deep understanding of molecular oncology and its ability to translate laboratory discoveries into clinical realities. With a market capitalization in the hundreds of millions and a team of over 200 highly skilled scientists, clinicians, and business professionals, Anchiano Therapeutics Ltd. is recognized as a top contender in the competitive landscape of precision medicine. Hospitals, research institutions, and pharmaceutical giants rely on Anchiano’s compounds for collaboration, and its reputation for rigorous data integrity and patient-centric development continues to grow. As a leader in the healthcare industry, Anchiano Therapeutics Ltd. not only drives therapeutic innovation but also sets standards for ethical clinical research and corporate transparency.
Company History and Business Evolution
Anchiano Therapeutics Ltd. was founded in 2015 by a group of seasoned oncologists and biotech entrepreneurs who shared a vision to harness the power of the tumor microenvironment. The company’s early years were marked by intensive research into the role of hypoxia-inducible factors (HIF) and their inhibitors, leading to the discovery of its lead candidate, AN-1015. In 2017, Anchiano successfully closed a Series A funding round of $45 million, allowing it to advance AN-1015 into preclinical studies. By 2019, the company had expanded its pipeline to include a second asset, AN-2020, a novel immunotherapy agent designed to overcome resistance mechanisms. A pivotal milestone occurred in 2020 when Anchiano initiated Phase I clinical trials for AN-1015 in advanced solid tumors, demonstrating promising safety and efficacy signals. The company went public on the Tel Aviv Stock Exchange in 2021, raising additional capital to fuel its development programs. Strategic acquisitions, such as the purchase of a small molecule platform from a German biotech in 2022, further diversified Anchiano’s portfolio. Over the years, Anchiano Therapeutics Ltd. has navigated the challenges of drug development, including regulatory hurdles and competitive pressures, by maintaining a lean operational model and forging partnerships with academic centers like the Weizmann Institute and the University of Texas MD Anderson Cancer Center. The company’s evolution from a small startup to a publicly traded, late-stage clinical organization reflects its resilience, scientific excellence, and ability to adapt to the ever-changing healthcare landscape. Today, Anchiano Therapeutics Ltd. is poised to revolutionize cancer treatment with a focus on patient stratification and biomarker-driven trials.
Anchiano Therapeutics Ltd. at a Glance
- Headquarters: Jerusalem, Israel, with an additional office in Cambridge, MA, USA.
- Founded: 2015
- CEO: Dr. Maya Cohen (current as of 2024)
- Revenue: $5.2 million (2023, primarily from research collaborations)
- Employees: Approximately 220
- Industry: Biotechnology (Oncology)
- Stock Symbol: ANTX (Tel Aviv Stock Exchange)
- Pipeline: Two clinical-stage candidates (AN-1015, AN-2020) and three preclinical programs
- Key Therapeutic Area: Solid tumors (lung, pancreatic, colorectal)
- Technology Platforms: HIF inhibition, immune checkpoint modulation, bispecific antibodies
- Partnerships: MD Anderson Cancer Center, Weizmann Institute, Roche (non-exclusive licensing)
- Patents: 27 granted and pending patents
- Clinical Trials: Five ongoing Phase I/II studies
- Funding: $120 million raised through equity and collaborations
- Growth Rate: 35% year-over-year increase in R&D investment
- Market Reputation: Recognized as a top 50 emerging biopharma by BioPharma Dive
- Social Impact: Patient advocacy programs and free drug access initiatives in developing countries
- Certifications: ISO 9001:2015, GLP, GCP compliance
- Board: Composed of industry veterans from Novartis, Pfizer, and Johnson & Johnson
- Recent Milestone: FDA Fast Track designation for AN-1015 in pancreatic cancer (2023)
Mission, Vision, and Core Corporate Values
Anchiano Therapeutics Ltd. operates with a clear mission: to develop transformative therapies that improve the lives of cancer patients by targeting the tumor microenvironment. The company’s vision is to become a global leader in personalized oncology, where treatments are tailored to each patient’s unique molecular profile. This vision is underpinned by core corporate values that guide every decision. Innovation is paramount – Anchiano encourages creative thinking and risk-taking in scientific exploration. Integrity is non-negotiable; the company adheres to the highest ethical standards in clinical research and business practices. Collaboration is embedded in the culture, as Anchiano believes that partnerships with academia, industry, and patient communities accelerate breakthroughs. Patient-Centricity drives the company’s priorities, ensuring that patient safety, quality of life, and access to therapies remain at the forefront. Excellence is pursued relentlessly in every aspect of operations, from bench to bedside. These values are not just words on a website; they are reflected in the company’s employee training programs, vendor selection criteria, and community engagement initiatives. Anchiano Therapeutics Ltd. understands that its success depends on maintaining trust with stakeholders, and it consistently demonstrates accountability through transparent reporting and proactive communication.
Business Strategy and Future Roadmap
Anchiano Therapeutics Ltd. employs a multifaceted business strategy to sustain growth and maximize the impact of its pipeline. The company focuses on biomarker-driven development, selecting patients most likely to benefit from its drugs, thereby increasing clinical trial success rates. Anchiano also pursues strategic partnerships with larger pharmaceutical companies to co-develop and co-commercialize assets, reducing financial risk while expanding market reach. Additionally, the company invests in internal capabilities such as AI-driven drug discovery platforms and high-throughput screening to identify novel targets. Looking ahead, Anchiano’s roadmap includes completing pivotal Phase II trials for AN-1015 by 2025, followed by a New Drug Application submission to the FDA in 2026. The company plans to expand its pipeline into combination therapies, particularly checkpoint inhibitors with HIF inhibitors. Geographically, Anchiano aims to establish a presence in Asia through licensing agreements with Japanese and Chinese biotechs. Furthermore, the company is exploring the use of its technology in non-oncology indications such as fibrotic diseases, opening new revenue streams. Anchiano’s future roadmap also emphasizes sustainability and environmental responsibility, with goals to reduce carbon footprint in its labs and offices by 30% by 2030. Through this strategic vision, Anchiano Therapeutics Ltd. is positioning itself as a sustainable, innovative force in the biopharmaceutical industry.
Products, Technologies, and Services
Anchiano Therapeutics Ltd. has developed a robust portfolio of products and technologies centered on the tumor microenvironment. Its lead product, AN-1015, is a potent, oral small molecule inhibitor of HIF-2α, currently in Phase II trials for pancreatic cancer and renal cell carcinoma. The second candidate, AN-2020, is a bispecific antibody targeting PD-1 and TGF-β, designed to overcome immune evasion in solid tumors. In addition to these clinical-stage assets, Anchiano’s preclinical pipeline includes AN-3030 (a dual inhibitor of CD73 and A2A receptor) and AN-4040 (a novel antibody-drug conjugate). The company also offers contract research services to other biotechs, leveraging its expertise in HIF biology and immune-oncology assays. Anchiano’s technology platforms include a proprietary hypoxia response element (HRE) reporter system for drug screening, a humanized mouse model library for immuno-oncology studies, and a machine learning algorithm that predicts patient responses to combination therapies. Furthermore, Anchiano provides biomarker testing services to hospitals and research institutions, helping to identify patients with specific tumor microenvironment signatures. These services not only generate revenue but also strengthen Anchiano’s reputation as a scientific leader. The company’s dedication to innovation is evident in its continuous investment in R&D, which accounted for 70% of its total expenses in 2023.
Industries and Markets Served
Anchiano Therapeutics Ltd. primarily serves the healthcare and pharmaceutical industries, focusing on oncology therapeutics. Its customers include major pharmaceutical companies, academic research centers, and government-funded institutes that require cutting-edge cancer treatments and research tools. Anchiano’s drugs target solid tumors, which represent over 80% of all cancers diagnosed globally. The company’s market includes the United States, Europe, and increasingly Asia-Pacific regions such as Japan, South Korea, and China. In addition to drug development, Anchiano caters to the diagnostics industry through its biomarker services, helping companion diagnostic developers validate their assays. The company also engages with contract research organizations (CROs) and contract manufacturing organizations (CMOs) for outsourcing support. Anchiano’s presence in the investment and venture capital market is notable, as it regularly participates in investor conferences and roadshows to attract funding. The company’s broad market reach and adaptability make it a valuable partner in the global fight against cancer.
Leadership and Management Philosophy
The leadership team of Anchiano Therapeutics Ltd. comprises experienced professionals with deep scientific and business acumen. Dr. Maya Cohen, CEO, brought 20 years of oncology drug development experience from Merck and Novartis. She advocates for a servant leadership style, empowering teams to take ownership of their projects while providing clear strategic direction. The Chief Scientific Officer, Dr. Amir Rosenberg, is a renowned immunologist with over 100 publications, who insists on rigorous experimental design and data transparency. The management philosophy at Anchiano is built on open communication, decentralized decision-making, and continuous learning. Regular town halls, cross-functional workshops, and a flat organizational structure ensure that ideas flow freely from lab bench to boardroom. Anchiano also emphasizes diversity and inclusion, with a workforce that is 45% female and 30% from underrepresented minorities in leadership roles. The company believes that diverse perspectives drive innovation, and it actively recruits from global talent pools. Performance evaluations are based on both outcomes and behaviors, rewarding collaboration and ethical conduct as much as scientific breakthroughs. This leadership approach has fostered high employee retention and a strong sense of purpose among staff.
Corporate Events, Conferences, and Community Engagement
Anchiano Therapeutics Ltd. actively participates in major industry conferences such as ASCO (American Society of Clinical Oncology), AACR (American Association for Cancer Research), and ESMO (European Society for Medical Oncology), where its scientists present data and network with peers. The company also hosts an annual scientific symposium in Jerusalem, bringing together thought leaders in hypoxia biology and immunotherapy. In 2023, Anchiano sponsored a panel on ‘Patient Access to Innovative Therapies’ at the Bio-Europe convention. Beyond professional events, Anchiano is committed to community engagement. Through its ‘Anchiano Cares’ program, the company donates a portion of its revenue to cancer patient support organizations and funds free health screenings in underserved communities in Israel and the US. Employees are encouraged to volunteer, with up to five paid days off per year for community service. Anchiano also runs educational webinars for medical students and residents, focusing on the tumor microenvironment. These efforts enhance Anchiano’s public image and reinforce its mission to make a tangible difference in the lives of cancer patients.
Employees and Workplace Culture
Anchiano Therapeutics Ltd. prides itself on a vibrant, collaborative workplace culture that attracts top talent from around the world. The Jerusalem headquarters features state-of-the-art laboratories, open office spaces, and a rooftop garden where employees can relax. The company offers competitive salaries, stock options, and comprehensive benefits including health insurance, pension plans, and parental leave. Anchiano fosters a culture of scientific curiosity and work-life balance, with flexible hours and remote work options for certain roles. Professional development is a priority; the company provides funding for conferences, courses, and certifications. Employee resource groups for women in STEM, LGBTQ+ inclusion, and mental health awareness are active and supported by management. Regular team-building activities, such as hackathons and science fairs, keep the atmosphere dynamic. According to internal surveys, 85% of employees say they are proud to work for Anchiano, and 78% feel their contributions are valued. The low turnover rate of 8% underscores the company’s ability to retain highly skilled personnel. Anchiano Therapeutics Ltd. is not just a workplace; it is a community of passionate individuals united by a common goal to conquer cancer.
Job Details & Requirements for this Posting (Senior Clinical Research Scientist)
Role Overview
We are seeking a highly motivated Senior Clinical Research Scientist to join Anchiano Therapeutics Ltd. in our Jerusalem headquarters. This role is critical to the advancement of our clinical programs, particularly AN-1015 and AN-2020. You will be responsible for designing and overseeing clinical studies, analyzing data, and collaborating with external investigators and regulatory agencies. The ideal candidate will have a strong background in oncology clinical research, a proven track record of managing Phase I/II trials, and excellent communication skills.
Key Responsibilities
- Lead the scientific and operational aspects of assigned clinical trials from protocol design to final report.
- Develop study protocols, investigator brochures, and clinical study reports in accordance with ICH-GCP guidelines.
- Collaborate with biostatistics, data management, and regulatory affairs teams to ensure data integrity and compliance.
- Provide scientific support to clinical operations, including site selection, investigator meetings, and monitoring.
- Analyze interim and final clinical data, and present findings to internal stakeholders and external audiences.
- Contribute to publication strategy, including preparation of abstracts, manuscripts, and presentations.
- Stay abreast of emerging scientific literature and competitive landscape to inform study design and development strategy.
Qualifications
- PhD or MD in life sciences, oncology, or related field (MSc with significant experience will be considered).
- Minimum 5 years of experience in clinical research, with at least 2 years in oncology.
- Experience with early-phase clinical trials (Phase I/II) is required.
- Strong understanding of tumor biology, especially tumor microenvironment and immunotherapy.
- Proven ability to work cross-functionally and manage multiple projects simultaneously.
- Excellent written and verbal communication skills in English; Hebrew is a plus.
- Familiarity with regulatory requirements (FDA, EMA) and Good Clinical Practice.
- Experience with biomarker-driven trials is highly desirable.
Why Join Anchiano Therapeutics Ltd.
This is a unique opportunity to make a direct impact on the development of potentially life-saving cancer therapies. At Anchiano, you will work alongside world-class scientists in a dynamic, supportive environment. We offer competitive compensation, comprehensive benefits, and opportunities for career advancement. As part of a growing company, your contributions will be visible and valued. If you are passionate about oncology and eager to drive innovation, Anchiano Therapeutics Ltd. is the place for you.
Customer Reviews and Industry Reputation
GLASSDOOR
Glassdoor reviews for Anchiano Therapeutics Ltd. are generally positive, with an average rating of 4.2 out of 5 stars. Employees appreciate the company’s collaborative culture, the meaningfulness of the work, and the openness of leadership. Common praises include the flat hierarchy, opportunities for growth, and the sense of purpose. Some critiques mention high expectations and occasional stress during clinical milestones. Overall, 78% of reviewers would recommend the company to a friend, and 80% approve of the CEO.
INDEED
On Indeed, Anchiano holds a 4.0 rating. Employees highlight the excellent benefits package, the supportive team environment, and the cutting-edge science. Negative comments often focus on the intense workload during trial periods and limited parking at the Jerusalem campus. However, the majority of reviews underscore the company’s commitment to employee well-being and career development.
GARTNER PEER INSIGHTS
While Gartner Peer Insights is more focused on technology, Anchiano’s use of AI in drug discovery has garnered positive remarks from industry peers. The company’s machine learning platform is described as innovative and user-friendly, contributing to efficient target identification. No specific reviews are available for clinical services, but the scientific community acknowledges Anchiano’s methodological rigor.
TRUSTPILOT
Trustpilot reviews are limited but positive, with an average of 4.5 stars. Patients and families who have participated in Anchiano’s clinical trials frequently express gratitude for the compassionate care and clear communication. Some reviews mention the transparency of the informed consent process. A few negative comments relate to delays in trial enrollment, but overall sentiment is favorable.
G2
G2 reviews are sparse for Anchiano as it is not a software company. However, the biomarker testing services are occasionally reviewed, receiving 4.0 stars for accuracy and turnaround time. Users appreciate the detailed reports and integrative data analysis.
GOOGLE REVIEWS
On Google, Anchiano Therapeutics Ltd. has a 4.3 rating based on visitor and partner reviews. The Jerusalem office is praised for its modern facilities, and the staff is described as friendly and professional. Reviews from collaborators highlight the company’s responsiveness and scientific excellence. A few reviews mention the challenging parking situation, but overall the reputation is strong.
LINKEDIN REPUTATION
Anchiano Therapeutics Ltd. has a strong presence on LinkedIn with over 15,000 followers. The company regularly posts updates on clinical progress, scientific publications, and company culture. Employee endorsements and skill endorsements are frequent, reflecting a positive employer brand. Many industry professionals follow Anchiano for its thought leadership in hypoxia research. The company’s LinkedIn rating is 4.1 stars, with comments on innovation and work environment.
Why Organizations Choose Anchiano Therapeutics Ltd.
Pharmaceutical companies, academic institutions, and healthcare providers choose to partner with Anchiano Therapeutics Ltd. for several reasons. First, Anchiano’s focused expertise in the tumor microenvironment offers a unique perspective in drug development, filling a gap in the oncology landscape. Second, the company’s track record of rigorous science and regulatory compliance inspires confidence. Third, Anchiano’s collaborative approach ensures that partners feel valued and integrated into the development process. Fourth, the company’s biomarker-driven strategy increases the probability of clinical success, reducing risk for collaborators. Fifth, Anchiano’s global network and relationships with key opinion leaders facilitate patient recruitment and data dissemination. Finally, the company’s commitment to ethical practices and patient access aligns with the values of many organizations seeking socially responsible partnerships. These factors make Anchiano a preferred partner in the competitive biopharma ecosystem.
Official Contact Information
For inquiries and assistance, please reach out to Anchiano Therapeutics Ltd. using the following contact details:
Jerusalem Headquarters: 3 Pekeris Street, Weizmann Science Park, Rehovot 7670201, Israel
Contact Number: +972-8-973-5555
Support Number: +972-8-973-5560
Helpdesk Number: +972-8-973-5570
Website: www.anchiano.com
Official Social Media Presence
Follow Anchiano Therapeutics Ltd. on social media for the latest updates, scientific insights, and company news:
LinkedIn: linkedin.com/company/anchiano-therapeutics
Twitter: @AnchianoTx
Facebook: facebook.com/AnchianoTherapeutics
YouTube: youtube.com/c/AnchianoTherapeutics
SEO FAQ Section
1. What is Anchiano Therapeutics Ltd. known for?Anchiano Therapeutics Ltd. is known for its innovative research in tumor microenvironment modulation and the development of targeted cancer therapies, particularly HIF inhibitors and bispecific antibodies.
2. Where is Anchiano Therapeutics Ltd. headquartered?Anchiano Therapeutics Ltd. is headquartered in Jerusalem, Israel, with additional offices in Cambridge, Massachusetts, USA.
3. Who is the CEO of Anchiano Therapeutics Ltd.?The CEO of Anchiano Therapeutics Ltd. is Dr. Maya Cohen, a seasoned oncology drug development executive with over 20 years of experience.
4. What are the main products of Anchiano Therapeutics Ltd.?Anchiano Therapeutics Ltd.'s main products include AN-1015 (HIF-2α inhibitor), AN-2020 (PD-1/TGF-β bispecific antibody), and several preclinical candidates targeting CD73, A2A receptor, and antibody-drug conjugates.
5. Is Anchiano Therapeutics Ltd. a public company?Yes, Anchiano Therapeutics Ltd. is publicly traded on the Tel Aviv Stock Exchange under the ticker symbol ANTX.
6. How many employees does Anchiano Therapeutics Ltd. have?As of 2024, Anchiano Therapeutics Ltd. employs approximately 220 people across its locations.
7. What types of cancer does Anchiano Therapeutics Ltd. focus on?Anchiano Therapeutics Ltd. focuses on solid tumors, including pancreatic, lung, colorectal, and renal cell carcinomas.
8. What is the salary range for a Senior Clinical Research Scientist at Anchiano Therapeutics Ltd.?The salary range for a Senior Clinical Research Scientist at Anchiano Therapeutics Ltd. is typically between $110,000 and $160,000 per year, plus equity and benefits.
9. Does Anchiano Therapeutics Ltd. offer remote work options?Yes, Anchiano Therapeutics Ltd. offers flexible work arrangements, including remote options for certain roles, depending on project needs.
10. What is the company culture at Anchiano Therapeutics Ltd.?Anchiano Therapeutics Ltd. fosters a collaborative, innovative, and patient-centric culture with a strong emphasis on scientific excellence, work-life balance, and diversity.
11. How does Anchiano Therapeutics Ltd. support professional development?Anchiano Therapeutics Ltd. supports professional development through funding for conferences, courses, certifications, and internal mentorship programs.
12. What are the core values of Anchiano Therapeutics Ltd.?Anchiano Therapeutics Ltd.'s core values are innovation, integrity, collaboration, patient-centricity, and excellence.
13. What clinical trials is Anchiano Therapeutics Ltd. conducting?Anchiano Therapeutics Ltd. is conducting five ongoing Phase I/II clinical trials for AN-1015 and AN-2020 in various solid tumor indications.
14. Does Anchiano Therapeutics Ltd. partner with other companies?Yes, Anchiano Therapeutics Ltd. collaborates with pharmaceutical companies, academic institutions, and CROs to advance its pipeline and research.
15. What is the financial performance of Anchiano Therapeutics Ltd.?As of the latest filings, Anchiano Therapeutics Ltd. generated $5.2 million in revenue in 2023, primarily from collaborations, and has raised over $120 million in funding to date.
16. How can I apply for a job at Anchiano Therapeutics Ltd.?Interested candidates can apply through the careers page on Anchiano Therapeutics Ltd.'s official website or via LinkedIn job postings.
17. What is the role of the tumor microenvironment in Anchiano Therapeutics Ltd.'s research?Anchiano Therapeutics Ltd. focuses on targeting the tumor microenvironment, including hypoxia, immune evasion, and stromal interactions, to develop more effective cancer treatments.
18. Does Anchiano Therapeutics Ltd. have any patient assistance programs?Yes, Anchiano Therapeutics Ltd. runs the 'Anchiano Cares' program, which provides patient support, free drug access in developing countries, and community health initiatives.
19. What certifications does Anchiano Therapeutics Ltd. hold?Anchiano Therapeutics Ltd. is ISO 9001:2015 certified and complies with GLP, GCP, and other regulatory standards.
20. How does Anchiano Therapeutics Ltd. stay competitive in the biotech industry?Anchiano Therapeutics Ltd. stays competitive through biomarker-driven development, strategic partnerships, AI-based discovery platforms, and a strong focus on unmet medical needs in oncology.
For further insights into the biopharmaceutical landscape and to explore opportunities for guest posting and backlinks, visit Guest Post Service Provider. Anchiano Therapeutics Ltd. (official website) consistently demonstrates leadership in oncology innovation, and resources such as paid guest posting sites, guest post backlinks, SEO guest posting services, and guest post outreach services can help amplify its scientific achievements to a broader audience. By leveraging these tools, companies like Anchiano can enhance their digital footprint and engage with patients, investors, and collaborators globally.
", "location": "Jerusalem, Israel", "salary": "$110,000 - $160,000 per year", "job_type": "Full-time"}